From Innovation to Access: Sunday Times Article Highlights Role of NanoKnife in Prostate Cancer Care

A recent article in The Sunday Times has brought national attention to the growing role of focal therapy in prostate cancer treatment and the limited access many UK patients still face. The piece highlights technologies including NanoKnife irreversible electroporation, which can precisely target cancerous tissue in the prostate while helping to preserve urinary continence and sexual function.

In the article, Professor Hashim Ahmed, Chair of Urology at Imperial College London, explains how focal therapy can offer effective cancer control, being an alternative option to surgery, radiotherapy and active surveillance, and he describes the introduction of NanoKnife as “genuinely game-changing” for suitable patients.

Clinical experience to date suggests that NanoKnife can offer effective tumour control with high rates of preserved urinary continence and erectile function, making it an important option to consider for appropriately selected patients.

As the UK distributor for NanoKnife, HC21 UK is committed in working with clinicians to increase access to evidence based focal therapy, so that treatment decisions can better reflect patients’ priorities around both cancer control and quality of life. We thank The Sunday Times for addressing this important topic and the many clinicians who have led the way in focal therapy.

Read the full article here.